DMPHF.US Dermapharm Holding SE
- Market cap
- USD 2.36B
- P/E
- 14.8x
- P/B
- 3.93x
- ROE
- 21.8%
- Dividend yield
- 2.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DMPHF.US undervalued?
Graham numberDMPHF.US trades 60.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dermapharm Holding SE fundamental analysis
No fundamental analysis for Dermapharm Holding SE yet.
Dermapharm Holding SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal e…
Full company profileDermapharm Holding SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dermapharm Holding SE annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 444M | 467M | 572M | 701M | 794M | 943M | 1.02B | 1.15B | 1.18B | 1.16B | 1.17B |
| Gross Profit | 201M | 221M | 300M | 384M | 463M | 621M | 661M | 704M | 767M | 392M | 397M |
| Operating Income | 86.8M | 92.1M | 108M | 120M | 137M | 298M | 244M | 183M | 217M | 222M | 256M |
| EBITDA | 106M | 112M | 140M | 168M | 182M | 357M | 324M | 263M | 317M | 314M | 355M |
| Net Income | 16.8M | 77.7M | 75.3M | 77.2M | 85.8M | 210M | 134M | 62.4M | 114M | 132M | 124M |
| EPS | 0.31 | 1.44 | 1.41 | 1.43 | 1.59 | 3.89 | 2.49 | 1.16 | 2.11 | 2.46 | 2.50 |
| Balance Sheet | |||||||||||
| Total Assets | 312M | 415M | 705M | 1.04B | 1.22B | 1.41B | 1.41B | 2.16B | 2.08B | 2.20B | 2.19B |
| Total Liabilities | 251M | 342M | 448M | 760M | 900M | 907M | 880M | 1.62B | 1.47B | 1.50B | 1.63B |
| Shareholders' Equity | 56.9M | 73.7M | 252M | 279M | 322M | 497M | 532M | 539M | 604M | 694M | 569M |
| Cash & Short-term Investments | 3.82M | 6.69M | 214M | 116M | 122M | 172M | 161M | 160M | 122M | 203M | 118M |
| Total Debt | 163M | 255M | 304M | 555M | 607M | 580M | 516M | 1.08B | 980M | 1.05B | 1.13B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 76.8M | 86.7M | 159M | 101M | 131M | 250M | 289M | 219M | 201M | 181M | 146M |
| Capital Expenditure | 17.8M | 74.7M | 26.0M | 46.4M | 40.8M | 61.2M | 39.0M | 41.5M | 38.2M | 42.1M | 52.6M |
| Free Cash Flow | 59.0M | 12.0M | 133M | 54.2M | 90.3M | 189M | 250M | 178M | 163M | 139M | 93.4M |
| Ratios | |||||||||||
| ROE | 29.6% | 105.5% | 29.8% | 27.7% | 26.7% | 42.1% | 25.3% | 11.6% | 18.8% | 19.1% | 21.8% |
| ROA | 5.4% | 18.7% | 10.7% | 7.4% | 7.0% | 14.9% | 9.5% | 2.9% | 5.5% | 6.0% | 5.7% |
| Net Profit Margin | 3.8% | 16.6% | 13.2% | 11.0% | 10.8% | 22.2% | 13.1% | 5.4% | 9.6% | 11.4% | 10.6% |
| Debt to Equity | 2.86x | 3.46x | 1.21x | 1.99x | 1.88x | 1.17x | 0.97x | 2.00x | 1.62x | 1.52x | 1.99x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dermapharm Holding SE dividends
- Dividend yield
- 2.11%
- Forward dividend
- 1.00 USD
- Payout ratio
- 36.6%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 48.4M | 0.90 | 36.6% |
| 2024 | EUR 47.4M | 0.88 | 41.6% |
| 2023 | EUR 56.5M | 1.05 | 90.6% |
| 2022 | EUR 117M | 2.17 | 87.0% |
| 2021 | USD 47.4M | 0.88 | 22.6% |
| 2020 | USD 43.1M | 0.80 | 50.2% |
| 2019 | USD 41.5M | 0.77 | 53.7% |
| 2018 | USD 41.5M | 0.78 | 55.0% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Dermapharm Holding SE
- Insiders 89.30%
- Institutions 6.56%
- Public & others 4.15%
- Shares outstanding 49.5M
- Free float 6.46M
Dermapharm Holding SE company profile
- Company name
- Dermapharm Holding SE
- Ticker
- DMPHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,619
- Fiscal year end
- December
- Address
- Lil-Dagover-Ring 7, Grünwald, Germany, 82031
- Phone
- 49 89 6 41 86 0
- Website
- ir.dermapharm.de
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
Dermapharm Holding SE management
4- Dr. Hans-Georg FeldmeierCEO & Chairman of the Management Board
- Mr. Christof DreibholzCFO, Chief Compliance Officer & Member of Management Board · born 1968
- Dr. Andreas EberhornChief Marketing Officer & Member of Management Board · born 1976
- Ms. Britta HambergerHead of Investor Relations & Corporate Communications